A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation

Background In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit of second-line treatment for high volume tumors or presence of more than five risk factors remain to be defined. Our aim was to develop and externally validate a new model most likely to correctly predict overa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Angiogenesis (London) 2019-08, Vol.22 (3), p.383-395
Hauptverfasser:	Derosa, Lisa, Bayar, Mohamed Amine, Albiges, Laurence, Le Teuff, Gwénaël, Escudier, Bernard
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical and Life Sciences Biomedicine Calibration Cancer Research Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - secondary Cardiology Cell Biology Classification Classification schemes Clinical trials Decision making Female Humans Kaplan-Meier Estimate Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - secondary Male Medical prognosis Medical research Metastases Metastasis Middle Aged Models, Biological Multivariate Analysis Neoplasm Metastasis Oncology Ophthalmology Original Paper Patients Prognosis Proportional Hazards Models Renal cell carcinoma Reproducibility of Results Risk analysis Risk Factors Risk groups Survival Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!